Understanding how genetic changes affect melanoma growth and spread
Defining epigenetic regulators of tumor heterogeneity and metastasis in melanoma
This study is looking at how changes in our genes might help melanoma, a type of skin cancer, become more varied and aggressive, and it needs tissue samples from patients to explore the role of a specific gene that could be important in this process.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10869947 on NIH RePORTER |
What this research studies
This research investigates the role of epigenetic changes in melanoma, particularly how these changes allow cancer cells to become more diverse and aggressive. By examining DNA methylation patterns in both primary and metastatic melanoma samples from patients, the study aims to identify specific genetic factors that contribute to the cancer's ability to spread. The researchers focus on a particular gene, NR2F2, which may play a crucial role in this process. Patients may be involved in providing tissue samples to help understand these mechanisms better.
Who could benefit from this research
Good fit: Ideal candidates for participation are patients diagnosed with cutaneous melanoma, particularly those with metastatic disease.
Not a fit: Patients with non-melanoma skin cancers or those without a diagnosis of melanoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing melanoma metastasis and improving treatment outcomes for patients.
How similar studies have performed: Previous research has shown that understanding epigenetic changes can lead to significant advancements in cancer treatment, suggesting this approach has potential for success.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Hernando, Eva — New York University School of Medicine
- Study coordinator: Hernando, Eva
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.